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Background: Prepubertal gynecomastia is a rare condition and most frequently classified as idiopathic. In
HIV-infected adults gynecomastia is a recognised but infrequent side-effect of antiretroviral treatment (ART)
and mostly attributed to efavirenz use. Gynecomastia should be distinguished from pseudogynecomastia as part
of the lipodystrophy syndrome caused by Nucleoside Reverse Transcriptase Inhibitors (NRTIs) to avoid incorrect
substitution of drugs. In the medical literature only five cases of prepubertal gynecomastia in children taking ART
are described and underlying pathogenesis was unknown. The occurrence of adverse effects of ART may interfere
with therapy adherence and long-term prognosis and for that reason requires attention. We report the first case
of prepubertal gynecomastia in a young girl attributed to efavirenz use.
Case presentation: A seven-year-old African girl presented with true gynecomastia four months after initiation
on ART (abacavir, lamivudine, efavirenz). History, physical examination and laboratory tests excluded known
causes of gynecomastia and efavirenz was considered as the most likely cause. Six weeks after withdrawal of
efavirenz the breast enlargement had completely resolved.
Conclusions: Efavirenz-induced gynecomastia may occur in children as well as in adults. With the increasing
access to ART, the possibility of efavirenz-exposure and the potential occurrence of its associated side-effects may
be high. In resource-poor settings, empirical change from efavirenz to nevirapine may be considered, providing
no other known or alarming cause is identified, as efavirenz-induced gynecomastia can resolve quickly after
withdrawal of the drug. Timely recognition of gynecomastia as a side-effect of efavirenz is important in order to
intervene while the condition may still be reversible, to sustain adherence to ART and to maintain the
sociopsychological health of the child.
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The clinical definition of gynecomastia is the presence
of a rubbery or firm mass extending concentrically from
the nipple of the breast, and the histological definition is
the benign proliferation of glandular breast tissue. When
the size of glandular tissue exceeds 0.5 cm in diameter
gynecomastia can usually be palpated [1,2]. Gynecomastia
should be distinguished from pseudogynecomastia which
is defined as fat deposition without glandular proliferation,* Correspondence: rph.peters@gmail.com
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distribution, and reproduction in any mediumand is often seen in the presence of obesity [1,3,4].
Pseudogynecomastia has been reported in HIV-infected
individuals taking antiretroviral treatment (ART) as part
of the fat redistribution syndrome [1,5-7].
Most cases of gynecomastia in children occur in the
neonatal period (due to placental transfer of estrogens) and
in puberty (due to an imbalance between estrogens and
androgens in the breast tissue); prepubertal gynecomastia
is rare. Two studies show that only five percent of children
with gynecomastia were prepubertal at diagnosis [3,8].
Isolated breast enlargement is usually referred to as
prepubertal gynecomastia or premature thelarche [2,3,9].
Prepubertal gynecomastia should always be considered
a pathological sign [2,3,10,11]. Although the majority ofCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of prepubertal gynecomastia including conditions of the
liver, kidney, thyroid, adrenal glands and testicles (Table 1)
[2,3,10,11]. In addition, various drugs have been associated
with development of gynecomastia including antibiotics,
neuropsychiatric medication and tuberculosis treatment
[1-3,12,13]. Moreover, in adults, gynecomastia has been
reported in association with most classes of antiretroviral
agents and with Human Immunodeficiency Virus (HIV)
infection itself [14,15]. There are very limited data on
this condition in HIV-infected children on ART. We re-
port on a prepubertal HIV-infected girl who developed
gynecomastia shortly after initiation of ART. Publication
of this case report was approved by the Human Ethics
Research Committee of the University of the Witwaters-
rand, Johannesburg, South Africa (Ref: M130273).
Case presentation
A 7-year old girl with HIV-infection presented at the
ART clinic of a hospital in rural Mopani District, South
Africa, with enlargement of both breasts since one month.
She had been initiated on ART four months before andTable 1 Causes of prepubertal gynecomastia [1-4,10,12]
Type Details
Idiopathic No known cause
Exposure to exogenous estrogens • Dermal and hair prepar
• Milk and meat of cows






Congenital adrenal hyperplasia • (Late-onset) 21-hydroxy
• 11-beta-hydroxylase def
• Overexpression of arom
Other hormonal aberrations • Androgen deficiency (e
• Androgen insensitivity
• Extraglandular aromatiz
Medication • Anti-androgens (e.g. bic
• Antimicrobials (e.g. anti
• Antineoplastic and imm
cyclosporine, methotrexa
• Gastrointestinal agents
• Cardiovascular (e.g. ami
calcium channel blockers
• Hormones (e.g. androge
• Neurologic/psychiatric (
• Drugs of abuse (e.g. alc
Abbreviations: GnRH Gonadotropin-releasing hormone, GH Growth hormone, TCAs Twas taking a regimen of abacavir, lamivudine and efavirenz.
She reported that the growth of her breasts occurred a
few weeks earlier, approximately ten to twelve weeks
after the start of ART. The breasts were slightly tender
but otherwise painless, and the breasts had stabilized in
size. She did not experience milky discharge from the
nipple nor had she or her mother observed any signs
that could be associated with early puberty such as
menstruation, acne and pubic or axillar hair growth.
Except from the breast enlargement she felt well and
did not have any other complaints. She did not take
any drugs of abuse or medication other than ART and
co-trimoxazole prophylaxis with correct doses for her
body weight.
Physical examination revealed bilateral glandular breast
tissue, which could easily be distinguished from fat tissue
through palpation. The breast gland tissue was about 4-5
cm in diameter, Tanner stadium 3, with the left breast
being more prominent than the right. There was no
discharge observed from the nipple. There were no
signs of lipodystrophy or puberty, in particular no pubic






.g. congenital adrenal hyperplasia)
ation of androstenedione (e.g. aromatase excess syndrome (AES), obesity)
alutamide, flutamide, finasteride, spironolactone)
retrovirals, isoniazid, ketoconazole, metronidazole, penicillamine)
unomodulators (e.g. alkylating agents, bleomycin, cisplatin,
te, vincristine)
(e.g. cimetidine, metoclopramide, omeprazole, ranitidine)
odarone, amlodipine, angiotensin-converting enzyme inhibitors,
, digitoxin, fibrates, reserpine, spironolactone, statins)
ns, chorionic gonadotropin, estrogens, GnRH agonist, GH)
e.g. haloperidol, methylphenidate, opioids, risperidone, TCAs)
ohol, amphetamines, heroin, marijuana, methadone)
ricyclic antidepressants.
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On clinical examination the thyroid gland was not
enlarged.
Blood tests were performed for liver and kidney function
and results were within the normal range. Blood hormone
levels were all in the normal range as well and were as
follows: thyroid-stimulating hormone (TSH) 5.12 mIU/L;
testosterone < 0.35 nmol/L; cortisol 129 nmol/L; follicle-
stimulating hormone (FSH) < 2 IU/L; luteinizing hormone
(LH) < 0.5 IU/L; estradiol < 92.0 ρmol/L; prolactin 6.6 μg/L.
The CD4 cell count was 302 cells/mm3 compared to 330
cells/mm3 at ART initiation; viral load was 174 copies/
mm3. Baseline viral load was not available in accordance
with South African treatment guidelines.
A clinical diagnosis of medication-induced gynecomastia
was considered and efavirenz was replaced with nevirapine
in her ART regimen (no history of previous nevirapine
exposure). At two weeks follow-up the breast size was
reduced by half to 2–3 cm in diameter and 4 weeks
later the gynecomastia had resolved completely.
Discussion and conclusion
The occurrence of adverse effects of ART is an important
determinant of therapy adherence and therefore of long-
term prognosis [16,17]. Gynecomastia is a recognised
but rare side-effect of ART in adult patients with an
estimated incidence of 2.8% in Western European male
patients treated with ART for more than two years [18].
Another study from Europe showed a similar incidence
of 2.9% (15 out of 516 patients) in male patients treated
with different ART-regimens [7]. In HIV-infected children
gynecomastia has only been reported on five occasions
[7,19-21]. Manfredi and colleagues described three cases
of gynecomastia confirmed by ultrasonography in boys
aged 11 years (1) and 12 years (2) with congenitally
acquired HIV disease [7,19]. These children were taking
a regimen of stavudine and didanosine with a protease-
inhibitor. No efavirenz exposure was reported and two
children presented with concurrent mild lipodystrophy
syndrome. Pubertal development was described as pre-
pubertal for two patients and for the latter it was not
described. The authors did not associate the develop-
ment of gynecomastia with a specific drug. Another
case report described the development of breasts in a
15 year old HIV-infected African boy two years after
his regimen was changed from abacavir, lamivudine and
nelfinavir to stavudine, didanosine and efavirenz because
of virological failure. Gynecomastia was persistent despite
withdrawal of efavirenz and eventually bilateral mastec-
tomy was required. This case was an adolescent boy
who already had gone through normal pubertal develop-
ment before the development of bilateral gynecomastia
[20]. Finally, a study from Uganda on occurrence of
side-effects in children on ART reported one case ofgynecomastia in a child taking zidovudine, lamivudine
and efavirenz, but information on age, pubertal stage,
follow-up and switch of regimen are not provided [21].
To our knowledge, we are the first to describe a case of
gynecomastia in a prepubertal child that can be attrib-
uted to efavirenz.
Efavirenz was the most likely cause of gynecomastia in
our case for several reasons. First, we could not identify
a recognised physical cause of gynecomastia in this
prepubertal girl through history, physical examination
and laboratory tests. Precocious puberty was ruled out as
no other signs of puberty were observed and gynecomastia
resolved after intervention. This suggests that the gyne-
comastia should be classified as either medication-induced
or idiopathic. Secondly, efavirenz is a recognised cause of
gynecomastia in adults on ART in whom withdrawal of
this drug from the ART regimen has been associated with
regression of symptoms [6,22]. A similar clinical course
is observed in our patient. Although gynecomastia has
been reported for almost all antiretroviral drugs, efavirenz
has been implicated far more frequently in adults
[6,7,14,22,23]. Finally, the time course of the complication
is suggestive of an association with efavirenz although this
does not prove causality: gynecomastia occurred relatively
quickly after introduction of the drug, the time period be-
tween initiation of ART and onset of symptoms (approxi-
mately 3 months) is similar to that described for adults,
and the gynecomastia resolved quickly after withdrawal
of the drug [6,22,23]. The resolution of gynecomastia
upon withdrawal of efavirenz in our child (6 weeks)
was much quicker than reported for spontaneous reso-
lution of idiopathic gynecomastia (0.8 – 2.6 years) in a
case series of 27 children with idiopathic gynecomastia
(not all prepubertal) of whom six showed spontaneous
resolution [3]. Altogether, we think that efavirenz is the
most likely causative agent of gynecomastia in our patient.
However we refrained from reintroducing efavirenz, which
could provide more substantiation of a causal association.
This hypothesis is supported by a plausible pathological
pathway of how efavirenz may induce gynecomastia.
The interaction of efavirenz with breast tissue causing
breast enlargement and increased risk of malignancy may
be indirect or direct. Sikora and colleagues demonstrated
direct binding of efavirenz to the estrogen-receptor-alpha
in the breast [24]. This receptor induces cell growth in an
17β-oestradiol-dependent breast cancer model. A different
theory relates to gynecomastia occurring as an immune
restoration phenomenon whereby cytokine and hormonal
balances are disturbed [14]. The latter theory does not
apply to our case as there was no change in CD4 count
observed since initiation of ART and viral load was not yet
fully suppressed.
The natural course of efavirenz-associated gynecomastia
is under debate in the literature. One case study described
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(80%) after a mean period of two months without any
specific therapy [14]. Another study showed only partial
spontaneous regression of breast hypertrophy in two
out of six patients (33%) without treatment modification
[23]. A case series described persistence of gynecomastia
in three patients without intervention, with one patient
requiring mastectomy [22]. Manfredi and colleagues re-
ported stabilisation of breast development when efavirenz
was continued [7]. Finally one study reported withdrawal
of efavirenz as intervention with complete resolution of
gynecomastia in all five patients in a mean period of five
months [6].
Recognition of gynecomastia as a side-effect of efavirenz
use is important with efavirenz being a preferred com-
ponent of first-line treatment regimen of HIV-infection
worldwide. Taking into consideration the increasing access
to ART, the potential for efavirenz-exposure and its
associated side-effects is large [25]. Furthermore the
occurrence of side-effects is known to be the most fre-
quent reason of discontinuation of at least one drug in
the initial regimen in the first year after ART initiation
[17]. Socio-psychological affliction is another major
reason to manage this side-effect intensively. Young
children, especially boys, with breast development have
been reported to suffer from cultural and social stigma
[3,4,20,26,27]. In addition prepubertal children with
gynecomastia may be considered sexually mature at too
young an age. Timely recognition of drug-induced gyne-
comastia offers the possibility of non-invasive intervention
because the condition is reversible if recently developed,
but substantial regression is unlikely if existent for more
than a year as fibrotic tissue is usually present [1]. As
described previously the differential diagnosis of gyne-
comastia is broad and the most important diagnosis to
be ruled out is a breast malignancy. A meta-analysis of the
incidence of non-AIDS-defining cancers in HIV-infected
patients showed that the incidence of breast cancer has
significantly increased since the implementation of
ART as standard therapy [28]. It remains to be seen if
the estrogenic activity of efavirenz may promote breast
cancer.
Although gynecomastia may be rare, it is important to
educate healthcare workers about this condition and on
how to differentiate between gynecomastia and lipody-
strophy on physical examination. This distinction is
important to avoid incorrect substitution of drugs as
lipodystrophy is usually caused by nucleoside reverse
transcriptase inhibitors (NRTIs). In resource-poor settings
in Africa where diagnostic facilities are not available, an
empirical switch from efavirenz to nevirapine may be
considered providing history, physical examination and
basic laboratory tests do not reveal a known cause. The
substitution of nevirapine for efavirenz is consideredsafe and maintains virological suppression in most patients
[29]. In addition nevirapine-based regimens show com-
parable activity to efavirenz-based regimens [25].
In conclusion, this case report shows that efavirenz
may induce gynecomastia in prepubertal HIV-infected
children on ART with complete resolution after withdrawal
of efavirenz. Early recognition and differentiation from
lipodystrophy are important to timely and correctly
manage this side-effect in order to improve health, sus-
tain adherence to ART and to reduce psychosocial
stigma.
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